Streptococcus Salivarius K12@Lip@GSH Alleviates Oral Mucositis in Patients Undergoing Radiotherapy

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

June 7, 2024

Primary Completion Date

August 10, 2024

Study Completion Date

September 12, 2024

Conditions

Oral Mucositis

Interventions

DRUG

SsK12@Lip@GSH

SsK12@Lip@GSH powder contained 1×10\^9 CFU viable cells of SsK12@Lip@GSH as the active ingredient.

Trial Locations (1)

Department of Oncology，The General Hospital of Western Theater Command, Chengdu

All Listed Sponsors

lead

The General Hospital of Western Theater Command

OTHER

NCT06446180 - Streptococcus Salivarius K12@Lip@GSH Alleviates Oral Mucositis in Patients Undergoing Radiotherapy | Biotech Hunter | Biotech Hunter